Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Digital nudge aims to speed up genetic testing for lung cancer

NCT ID NCT05853887

Knowledge-focused Sponsor: Charu Aggarwal Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether an electronic health record reminder (a 'nudge') can prompt doctors to order genetic tests for patients newly diagnosed with advanced non-small cell lung cancer. The goal is to have test results available before starting treatment, so doctors can choose the best therapy. About 260 patients at several Penn Medicine locations will take part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Electronic health record nudge (a reminder alert for doctors)
What this could lead to
If successful, this could show that simple digital reminders help doctors get genetic test results faster, leading to more personalized treatment for lung cancer patients.
What could go wrong
This is a behavioral study, not a drug trial, so it won't directly treat cancer. The nudge may not change doctor behavior significantly, and results may not apply to other hospitals or cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

260 people

The number who actually took part.

Started

Jun 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants with a histological, or cytological diagnosis of metastatic non-squamous (mNSq) non-small cell lung cancer (NSCLC) who have not yet received systemic treatment for metastatic disease. * Participants must be seen at Lancaster General Health (LGH), Penn Presbyterian Medical Center (PPMC), Penn Medicine Cherry Hill (PMCH), Penn Medicine Princeton Health (PMPH), Penn Medicine Voorhees (PMV) or Penn Medicine Washington Township (PMWT) for mNSq NSCLC. Exclusion Criteria: * Participants with incomplete staging information. * Children, pregnant women, fetuses, neonates, or prisoners are not included in this research study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Newly diagnosed NSCLC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Newly diagnosed NSCLC Non-small cell lung cancer metastatic Non-squamous non-small cell neoplasm of lung

Contacts and locations

Locations

  • Penn Medicine Cherry Hill

    Cherry Hill, New Jersey, 08003, United States

  • Penn Medicine Lancaster General Health

    Lancaster, Pennsylvania, 17602, United States

  • Penn Medicine Princeton Health

    Plainsboro, New Jersey, 08536, United States

  • Penn Medicine Voorhees

    Voorhees Township, New Jersey, 08043, United States

  • Penn Medicine Washington Township

    Sewell, New Jersey, 08080, United States

  • Penn Presbyterian Medical Center

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.